gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Intravitreal injection of Methotrexate for choroidal neovascularisations in age-related macular degeneration (AMD)

Meeting Abstract

  • corresponding author S.E. Karl - Department of Ophthalmology of the University of Bonn
  • A. Bindewald - Department of Ophthalmology of the University of Bonn
  • F. Roth - Department of Ophthalmology of the University of Bonn
  • T.U. Krohne - Department of Ophthalmology of the University of Bonn
  • N. Eter - Department of Ophthalmology of the University of Bonn
  • F.G. Holz - Department of Ophthalmology of the University of Bonn

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogP 158

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 22. September 2004

© 2004 Karl et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




Methotrexate (MTX) has immunosupressive, antiproliferative and antiangiogenetic properties and is widely used in the treatment of rheumatic diseases and ocular inflammatory disorders. Recent studies indicate a role of inflammatory cells and their expression of angiogenetic factors in the pathogenesis of chorioidal neovascularisations. We investigate the effect of repeated i ntra v itreal M TX (IVM) injections in eyes with neovascular AMD.


In a phase-I-study IVM-injections are performed once per week in a dose of 400μg MTX in 0,1ml per injection. Animal studies demonstrated therapeutic concentrations of this dose without adverse effects. Baseline and review examinations include ETDRS visual acuity, fluorescein angiography, optical coherence tomography and complete blood count.


In this on-going study we recruit patients ≥55 years of age with AMD and active, subfoveal occult CNV, visual acuity between 20/230 and 20/40 in the study eye, and a lesion size of ≤5400 μm greatest linear diameter.


Repeated intravitreal injections have recently been shown to represent a safe form of drug application including triamcinolone and anti-VEGF-molecules with high therapeutic levels in the target tissue without adverse systemic effects. This route of administration appears also suitable for antiproliferative substances. We will present initial results on the effect of intravitreal MTX in AMD from this ongoing phase-I-trial.